Navigation Links
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Date:1/31/2008

ell counts, including leukopenia (low white blood cell count), thrombocytopenia (low platelet count) and neutropenia (low neutrophil count); thyroiditis (inflammation of the thyroid gland); and autoimmunity (production of antibodies against the body's own tissues.)

Depression and suicidal behavior, including suicidal ideation, suicidal attempts and completed suicides, have been reported in association with treatment with alfa interferons.

Important Safety Information Regarding U.S. Labeling for PEGINTRON(TM) Alpha interferons, including PEGINTRON(TM) and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON(TM) and/or INTRON(R) A therapy.

Contraindications

PEGINTRON(TM) is contraindicated in patients with hypersensitivity to PEGINTRON(TM) or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score >6 [class B and C]) in cirrhotic CHC patients before or during treatment. INTRON(R) A (Interferon alfa-2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON(R) A or any component of the product, autoimmune hepatitis, and decompensated liver disease.

Incidence of adverse events

There are no new adverse events specific to PEGINTRON(TM) as compared to INTRON(R) A; however, the incidence of some (eg, injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON(TM) were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all wer
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Last week, Representatives Gus Bilirakis (R-FL) ... bold bipartisan step on behalf of patients with ... co-sponsors of the legislation include Representatives McCaul (R-TX) ... makers and innovators to "repurpose" major market drugs ... opens the door to the development of hundreds ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... S.A., a,French drug and diagnostic discovery company, today announces ... 2007., 2007 Key Events, - Milestone reached ... AGN ) in view of the initiation of Phase ... - Approval by the AFSSAPS (Agence Francaise de ...
... Germany, March 5 In mid-March the German,Bundestag (Lower ... the German Stem,Cell Act. The opposing poles in the ... apart: its proponents are calling for the complete,liberalisation of ... of a,general ban on the use of human stem ...
... Statins Alone, in Decreasing Cardiovascular Events in Diabetics with Haptoglobin ... ... March 5 Synvista,Therapeutics, Inc. (Amex: SYI ) announces the publication ... E to statin therapy prevented more cardiovascular events (heart,attack, stroke and cardiovascular ...
Cached Biology Technology:ExonHit Therapeutics - 2007 Financial Results 2ExonHit Therapeutics - 2007 Financial Results 3ExonHit Therapeutics - 2007 Financial Results 4ExonHit Therapeutics - 2007 Financial Results 5ExonHit Therapeutics - 2007 Financial Results 6ExonHit Therapeutics - 2007 Financial Results 7ExonHit Therapeutics - 2007 Financial Results 8ExonHit Therapeutics - 2007 Financial Results 9ExonHit Therapeutics - 2007 Financial Results 10ExonHit Therapeutics - 2007 Financial Results 11ExonHit Therapeutics - 2007 Financial Results 12A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 2Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 4
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... (November 4, 2014) — Think about the way our ... do neighboring cells know that they are supposed to ... do these tissues find the correct place and alignment? ... these crucial questions. , In a new study, UM ... communicate with their surrounding neighbors, at the head-trunk region. ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... diabetes during pregnancy is directly controlled by serotonin, a ... a neurotransmitter, and is influenced by the amount of ... to new findings of an international team led by ... to simple dietary solutions and possible therapeutics for the ...
... rich? Smithsonian researchers have new evidence that the answer ... to a study published in the journal, Nature ., ... not grow and survive well under their mothers or other ... fellow at the University of WisconsinMilwaukee and the Smithsonian Tropical ...
... available in Spanish . , At a time ... Service (ARS)-funded scientists have contributed to a limited but growing ... cognitive function. Cognitive function is measured by the ... use available information for activities of daily life. Alzheimer,s disease, ...
Cached Biology News:Gestational diabetes linked to serotonin and dietary protein 2Gestational diabetes linked to serotonin and dietary protein 3Biodiversity's holy grail is in the soil 2Vitamin D and mental agility in elders 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Viruses microRNA Microarray ...
Biology Products: